Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JMKX003801 in Healthy Participants
NCT06549309Phase 1Recruiting
- Sponsor
- Jemincare
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in gram-negative bacterial infections comparing JMKX003801 with Placebo (2 arms). Primary endpoint: Adverse events (AEs) at Day 3. Started Aug 2024; status: recruiting.
02
Drugs
JMKX003801
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT06549309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549309.